亚洲另类伦春色综合,www.四虎影视.com,亚洲宗合

AbbVie's Q1 2025 Financial report Financial statements AbbVie’s Q1 2025 report reveals soaring sales of Skyrizi and Rinvoq amid Humira’s decline. Explore how innovation, competition, and strategic shifts are reshaping AbbVie’s future in immunology and beyond.
Roche's Q1 2025 Financial report Financial statements Roche Q1 2025 financial results show 6% revenue growth, driven by strong demand for innovative drugs and diagnostics. China leads international growth, while the company makes strategic investments in the US and global R&D.
Merck's Q1 2025 Financial report Financial statements Merck's Q1 2025 earnings show a 2% decline in revenue, with strong growth in KEYTRUDA and animal health products. The company faces short-term challenges but continues to drive innovation in its R&D pipeline.
Sanofi's Q1 2025 Financial report Sanofi Sanofi's Q1 2025 report shows a 9.7% sales growth, driven by Dupixent and innovative drugs. The company confirms full-year guidance with strong performance in immunology, rare diseases, and vaccines.
BMS's Q1 2025 Financial report Market Trend Bristol Myers Squibb Q1 2025 earnings: revenue down 6% YoY, but strong product performance drives EPS growth. Full-year guidance raised. Highlights include Opdivo, Reblozyl, and Breyanzi.
AkzoNobel Q1 2025 Earnings Report Market Trend AkzoNobel reports €2.613B Q1 2025 revenue with strong marine and protective coatings growth. CEO outlines resilience amid tariffs and economic uncertainty. Adjusted EBITDA margin at 13.7%.
Johnson & Johnson's Q1 2025 Financial report Johnson & Johnson Johnson & Johnson's Q1 2025 report shows a 135% sales surge for CARVYKTI, a CAR-T therapy co-developed with Legend Biotech, with projected annual sales hitting $2B. Oncology drug sales also saw strong growth.
RPM International's Financial report 2024 Market Trend RPM International reports $5.3B in revenue for the first three quarters of FY2025, down 0.68% YoY. Q3 sales fell due to weather and weak OEM demand. 8 plants merged under MAP 2025.
Tronox to Close Dutch Plant as Titanium Dioxide Revenue Grows to $2.41 Billion Market Trend Tronox Holdings announces the closure of its Botlek plant in the Netherlands, as it focuses on optimizing assets and reducing costs. Despite challenges, its titanium dioxide revenue reached $2.41 billion in 2024.
Iovance Biotherapeutics 2024 Financial report Financial statements Iovance Biotherapeutics reports 2024 revenue of $164 million, with its TIL therapy Amtagvi (Lifileucel) generating $103.6 million in sales. The company expects 2025 revenue of $450M to $475M.

< Pre 1...5 6 789 10 11...15 Next >

Articles Archives

Hot Articles

All Categories

Agri & Industry Cosmetic Laboratory Pharmaceutical Food

永久免费毛片_亚洲成人看片_亚洲春色另类_亚洲综合免费视频_最新高清无码专区_午夜影院a